Multiple point action mechanism of valproic acid-teratogenicity alleviated by folic acid, vitamin C, And N-acetylcysteine in chicken embryo model

Toxicology

Volumn 291, Issue 1-3, 2012, Pages 32-42

  Hsieh, Chiu Lan ^a   Wang, Hui Er ^b   Tsai, Wan Jane ^a   Peng, Chiung Chi ^c,d   Peng, Robert Y ^b,d  

^a NATIONAL CHANGHUA UNIVERSITY OF EDUCATION   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Ascorbic acid; Folic acid; Histone deacetylase; N acetylcysteine; Valproic acid

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLCYSTEINE; APOENZYME; ASCORBIC ACID; DIHYDROFOLATE REDUCTASE; DIHYDROFOLIC ACID; FOLIC ACID; GLUTAMIC ACID; GLUTATHIONE; HISTONE DEACETYLASE; HOMOCYSTEINE; HYDROGEN PEROXIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NUTRACEUTICAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE DISMUTASE; VALPROIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHICKEN; CONGENITAL MALFORMATION; DOWN REGULATION; EMBRYO; IN VIVO CULTURE; IN VIVO STUDY; MORTALITY; NECK MUSCLE; NONHUMAN; PRIORITY JOURNAL; TERATOGENICITY; UPREGULATION;

ACETYLCYSTEINE; ANIMALS; ANTICONVULSANTS; ANTIOXIDANTS; ASCORBIC ACID; CHICK EMBRYO; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FOLIC ACID; FOOT DEFORMITIES; GLUTATHIONE; HINDLIMB; HISTONE DEACETYLASES; HOMOCYSTEINE; HYDROGEN PEROXIDE; JOINTS; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; SUPEROXIDE DISMUTASE; TERATOGENS; TISSUE EMBEDDING; VALPROIC ACID; VITAMINS;

EID: 84155164936     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.10.015     Document Type: Article

References (61)

1. Aluclu M.U., Tuncer M.C., Guzel A., Aluclu M.A., Akkus M. The effects of valproic acid on sciatic nerve of fetal rats and protective effects of folic acid and vitamin E. Int. J. Morphol. 2009, 27:285-294.
2. Amorim M.R., Lima M.A., Castilla E.E., Orioli I.M. Non-Latin European descent could be a requirement for association of NTDs and MTHFR variant 677C>T: a meta-analysis. Am. J. Med. Genet. A 2007, 143A:1726-1732.
3. Barreiro E., Sánchez D., Gáldiz J.B., Hussain S.N.A., Gea J. N-acetylcysteine increases manganese superoxide dismutase activity in septic rat diaphragms. Clin. Respir. Physiol. 2005, 26:1032-1039.
4. Neural Tube Defects-Congress W3 C161F Ciba Foundation 1994, 181. John-Wiley & Son Ltd., West Sussex, England.
5. Botto L.D., Yang Q. 5,10-Methylelenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am. J. Epidemiol. 2000, 151:862-877.
6. Chango A., Nour A.A., Bousserual S., Eveillard D., Anton P.M., Gueant J.L. Time course gene expression in the one-carbon metabolism network using HepG2 cell line grown in folate-deficient medium. J. Nutr. Biochem. 2009, 20:312-320.
7. Chen C.S., Wang Y.C., Yang H.C., Huang P.H., Kulp S.K., Yang C.C., Lu Y.S., Matsuyama S., Chen C.Y. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double strand breaks by targeting Ku70 acetylation. Cancer Res. 2007, 67:5318-5327.
8. Dawson J.E., Raymond A.M., Winn L.M. Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. Toxicol. Appl. Pharmacol. 2006, 211:124-132.
9. Dennery P.A. Effects of oxidative stress on embryonic development. Birth Defects Res. C Embryo Today 2007, 81:155-162.
10. Ehlers K., Elmaza M.M.A., Nau H. Methionine reduces the valproic acid-induced spina bifida rate in mice without altering valproic acid kinetics. J. Nutr. 1995, 126:67-75.
11. Eikel D., Lampen A., Nau H. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem. Res. Toxicol. 2006, 19:272-278.
12. 12 on valproic acid-induced teratogenesis in mice. Fundam. Appl. Toxicol. 1992, 18:389-394.
13. Faiella A., Werning M., Consalez G.G., Hostick U., Hofmann C., Hustert E., Boncinelli E., Balling R., Nadeau J.H. A mouse model for valproic acid teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum. Mol. Genet. 2000, 9:227-236.
14. Frick B., Schrocksnadel K., Neurauter G., Wirleitner B., Artner-Dworzak E., Fuchs E.D. Rapid measurement of total plasma homocysteine by HPLC. Clin. Chim. Acta 2003, 331:19-23.
15. Gilmour P., Rahman I., Donaldson K., MacNee W. Histone acetylation regulated epithelial IL-8 release mediated by oxidative stress from environmental particles. Am. J. Physiol. Lung Cell Mol. Physiol. 2003, 284:L533-L540.
16. Hamburger V., Hamilton H.L. A series of normal stages in the development of the chick embryo. J. Morphol. 1951, 88:49-92.
17. Hansen J.M. Oxidative stress as a mechanism of teratogenesis. Birth Defects Res. C Embryo Today 2006, 78:293-307.
18. Hermández-Di{dotless}áz S., Werler M.M., Walker A.M., Mitchell A.A. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am. J. Epidemiol. 2001, 153:961-968.
19. Hrzenjak A., Moinfar F., Kremser M.-L., Strohmeier B., Staber P.B., Zatloukal K., Denk H. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 2006, 5:2203-2210.
20. Huang P.-H., Chen C.-H., Chiu C.-C., Sargeant A.M., Kulp S.K., Teng C.-M., Byrd J.C., Chen C.-S. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation, in part, via transcriptional repression of histone H3 lysine 4 demethylases. Mol. Pharmacol. 2011, 79:197-206.
21. Huang R.F., Huang S.M., Lin B.S., Hung C.Y., Lu H.T. N-Acetylcysteine, vitamin C and vitamin E diminish homocysteine thiolactone-induced apoptosis in human promyeloid HL-60 cells. J. Nutr. 2002, 132:2151-2156.
22. Jelinek R., Peterka M. Chick embryotoxicity screening test-130 substances tested. Ind. Exp. Biol. 1985, 23:588-595.
23. Jenkinson P.C., Anderson D., Gangolli S.D. Malformations induced in cultured rat embryos by enzymically generated active oxygen species. Teratog. Carcinog. Mutagen. 1986, 6:547-554.
24. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem. Int. 2000, 37:103-111.
25. Johnstone R.W. Histone deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1:287-299.
26. Karabiber H., Sommezgoz E., Ozerol E., Yakinci C., Otlu B., Yologlu S. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev. 2003, 25:113-115.
27. Kelly T.L.J., Neaga O.R., Schwahn B.C., Rozen R., Trasler J.M. Infertility in 5,10-methylenetetrahydrofolate reductase (MTHFR)-deficient male mice is partially alleviated by lifetime dietary betaine supplementation. Biol. Reprod. 2005, 72:667-677.
28. Kerksick C., Willoughby D. The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. J. Int. Soc. Sports Nutr. 2005, 2:38-44.
29. Koch S., Jager R.E., Losche G., Nau H., Rating D., Helge H. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Pediatr. 1996, 84:739-746.
30. Kwon H.J., Kim M.S., Kim M.J., Nakajima H., Kim K.W. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 2002, 97:290-296.
31. Lheureux P.E.R., Penaloza A., Zahir S., Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity-what is the evidence?. Crit. Care 2005, 9:431-440.
32. Lie O.V., Bennett G.D., Rosenquist T.H. The N-methyl-d-aspartate receptor in heart development: a gene knockdown model using siRNA. Reprod. Toxicol. 2010, 29:32-41.
33. Lindhout D., Omtzigt J.G., Cornel M.C. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992, 42(4 Suppl. 5):111-118.
34. Marchetti M., Bovina C., Formiggini G., Tolomelli B. Folic acid metabolism in rapidly growing tissues: synthesis of pteroylpolyglutamates [Article in Italian]. Acta Vitaminol. Enzymol. 1982, 4:197-205.
35. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000, 92:1210-1216.
36. Mattiazzi M., D'Aurelio, Gajewski C.D., Martushova M., Kiaei M., Beal F., Manfredi G. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 2002, 277:29626-29633.
37. Meijer W.M., de Walle H.E.K., Kerstjens-Frederikse W.S., de Jong-van den Berg L.T.W. Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. Reprod. Toxicol. 2005, 20:203-207.
38. Menegola E.D., Di Renzo F., Broccia M.L., Giavini E. Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Res. 2006, 78:345-353.
39. Mominoki K., Kinutani M., Wakisaka H., Saito S. Leg dysfunctions in a hatched chick model of spina bifida aperta. Exp. Neurol. 2006, 197(1):133-142.
40. Nourooz-Zadeh J., Tajaddini-Sarmadi J., Wolff S.P. Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal. Biochem. 1994, 220:403-409.
41. Padmanabhan R., Shafiullah M., Benedict S., Nagelkerke N. Effect of maternal exposure to homocystine on sodium valproate-induced neural tube defects in the mouse embryos. Eur. J. Nutr. 2006, 45:311-319.
42. Parle-McDermott A., Kirke P.N., Mills J.L., Molloy A.M., Cox C., O'Leary V.B., Pangilinan F., Conley M., Cleary L., Brody L.C. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur. J. Hum. Genet. 2006, 14:768-772.
43. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J. Biol. Chem. 2001, 276:36734-36741.
44. Rodríguez-Bernaldo de Quirós A., Castro de Ron C., López-Hernández J., Lage-Yusty M.A. Determination of folates in seaweeds by high-performance liquid chromatography. J. Chromatogr. A. 2004, 1032:135-139.
45. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell. Mol. Life Sci. 2007, 64:2090-2103.
46. Rosenquist T.H., Chaudoin T., Finnell R.H., Bennett G.D. Hig receptor in cardiac neural crest migration: a gene knockdown model using siRNA. Dev. Dyn. 2010, 239:1136-1144.
47. Roy M., Leclerc D., Wu Q., Gupta S., Kruger W.D., Rozen R. Valproic acid increases expression of methylenetetrahydrofolate reductase (MTHFR) and induces lower teratogenicity in MTHFR deficiency. J. Cell Biochem. 2008, 105:467-476.
48. Sahambi S.K., Hales B.F. Exposure to 5-bromo-2'-deoxyuridine induces oxidative stress and activator protein-1 DNA binding activity in the embryo. Birth Defects Res. A Clin. Mol. Teratol. 2006, 76:580-591.
49. Schulpis K.H., Lazaropoulou C., Regoutas S., Karikas G.A., Margeli A., Tsakiris S., Papassotiriou I. Valproic acid monotherapy induces DNA oxidative damage. Toxicology 2006, 217:228-232.
50. Sen C.K. Antioxidant and redox regulation of cellular signaling: introduction. Med. Sci. Sports Exerc. 2001, 33:368-370.
51. Sha K., Winn L.M. Characterization of valproic acid-initiated homologous recombination. Birth Defects Res. B Dev. Reprod. Toxicol. 2010, 89:124-132.
52. Tabatabaei A.R., Abbott F.S. Assessing the mechanism of metabolism dependent valproic acid induced in vitro cytotoxicity. Chem. Res. Toxicol. 1999, 12:323-330.
53. van der Linden I.J.M., den Heijer M., Afman L.A., Gellekink H., Vermeulen S.H.H.M., Kluitmans L.A.J., Blom H.J. The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. J. Mol. Med. 2006, 84:1047-1054.
54. van der Put N.M., Blom H.J. Neural tube defects and a disturbed folate dependent homocysteine metabolism. Eur. J. Obstet. Gynecol. Reprod. Biol. 2000, 92:57-61.
55. van Gelder M.M.H.J., van Rooij I.A.L.M., Miller R.K., Zielhuis G.A., de Jong-van den Berg L.T.W., Roeleveld N. Teratogenic mechanisms of medical drugs. Hum Reprod. Update 2010, 16:378-394.
56. van Rooij I.A.L.M., Ocké M.C., Straatman H., Zielhuis G.A., Merkus H.M.W.M., Steegers-Theunissen R.P.M. Periconceptional folate intake by supplement and food reduces the risk of nonsyndromic cleft lip with or without cleft palate. Prev. Med. 2004, 39:689-694.
57. Verrotti A., Pascarella R., Trotta D., Giuva T., Morgese G., Chiarelli F. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res. 2000, 41:253-257.
58. Wells P.G., Kim P.M., Laposa R.R., Nicol C.J., Parman T., Winn L.M. Oxidative damage in chemical teratogenesis. Mutat. Res. 1997, 396:65-78.
59. Whitsel A.I., Johnson C.B., Forehand C.J. An in ovo chicken model to study the systemic and localized teratogenic effects of valproic acid. Teratology 2002, 66:153-163.
60. Yoshiura K., Nakaoka T., Nishishita T., Sato K., Yamamoto A., Shimada S., Saida T., Kawakami Y., Takahashi T.A., Fukuda H., Imajoh-Ohmi S., Oyaizu N., Yamashita N. Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clin. Cancer Res. 2005, 11:8201-8207.
61. Zhang B., Wang X., Nazarali A.J. Ascorbic acid reverses valproic acid-induced inhibition of Hoxa2 and maintains glutathione homeostasis in mouse embryos in culture. Cell. Mol. Neurobiol. 2010, 30:137-148.